Ad
related to: questcor stockschwab.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Mallinckrodt acquired this product via its acquisition of Questcor Pharmaceuticals in 2014. [81] When Questcor acquired the drug in 2001 it sold for $40 a vial; within a year of the acquisition Questcor raised the price of the drug to $1,500 per vial and to $28,000 by 2013. [82]
When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons, and decide whether it's possible upside outweighs its risks. Let's take a look at ...
Last November, Questcor's stock took a hit when the Food and Drug Administration granted orphan drug designation for Synacthen Depot in the treatment of infantile spasms to Cerium Pharmaceuticals ...
What: Shares of biotechnology company Questcor. ... So what: The stock has been pressured in recent months on concerns that reimbursement issues would hurt sales of its H.P. Acthar gel, but today ...
Let's face it. Some investors seemed spooked by Questcor's fourth-quarter results even though the company blew the doors off with fantastic sales and earnings growth that beat analyst projections.
It's been a dizzying (and likely nauseating) few months for shareholders in Questcor Pharmaceuticals (NAS: QCOR) . The stock shot up by 45% for the year by early July. Then shares plunged nearly ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Although we ...
After a panicked Questcor (NAS: QCOR) sell-off on Friday, the stock has stabilized. What was the cause for alarm? It turns out that Questcor's champion drug, Acthar -- which has an orphan ...